The Pharma Data

JANUARY 24, 2021

Bond joins Notch from Kite, where he most recently served as Vice President of Cellular Engineering. Dr. Bond has extensive experience in the discovery and development of adoptive cell therapies, monoclonal antibodies, and cellular engineering and genome editing. ” Chris Bond , Ph.D.,

Engineer 52

Engineer Gene Editing Genome Genomics 52

Advarra

NOVEMBER 29, 2022

Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline. But review issues are not the only problems.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

XTalks

JANUARY 6, 2025

Gene Editing CRISPR-Cas9 and related gene-editing technologies continue to advance, and today they are widely used to study and develop therapeutic approaches for a broad range of human diseases. The global next-generation biomanufacturing market is projected to grow at a CAGR of 14.85 billion by 2031.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111